Global Adenosine Triphosphate Swab Test Market Forecast to 2027 – COVID-19 Impact and Analysis – ResearchAndMarkets.com

Global Adenosine Triphosphate Swab Test Market Forecast to 2027 – COVID-19 Impact and Analysis – ResearchAndMarkets.com




Global Adenosine Triphosphate Swab Test Market Forecast to 2027 – COVID-19 Impact and Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Adenosine Triphosphate Swab Test Market Forecast to 2027 – COVID-19 Impact and Global Analysis By Type and Application” report has been added to ResearchAndMarkets.com’s offering.

The adenosine triphosphate (ATP) swab test market was valued at US$ 198.21 million in 2019 and is projected to reach US$ 369.71 million by 2027; it is expected to grow at a CAGR of 8.10% from 2019 to 2027.

HAIs, also known as nosocomial infections, are acquired while receiving treatment or therapies in healthcare facilities. These infections are related to surgical procedures and medical instruments used during procedures. HAIs are responsible for morbidity and mortality of significant number of patients in the world. According to a study published by the Centers for Disease Control and Prevention (CDC) in 2019, 1 in 31 hospital patients is estimated to have some kind of HAI. In addition, according to estimates by The European Centre for Disease Prevention and Control in 2019, ~4.1 million patients across Europe suffer due to HAIs every year. Furthermore, according to study published in the Journal of Antimicrobial Resistance & Infection Control in 2019, the incidence rate of HAIs in China was 3.62 per 1,000 patient days.

Out of this rate of incidence, respiratory tract infection accounted for 43.80% of infections while bloodstream and urinary tract infections accounted for 15.74% and 12.69% of infections, respectively. The hospital visits and patient pool is likely to increase in the coming years due to the mounting prevalence of chronic conditions and outbreaks of infectious diseases. HAIs also contribute to this increasing population of patients. For instance, the World Health Organization (WHO) estimates published in 2019, 421 million hospitalizations are conducted worldwide every year. Of these, 42.7 million patients suffer from adverse reactions or infections acquired at healthcare settings. Also, according to the same estimates, 50.0% of these adverse events are preventable in developed countries. Thus, such rising prevalence of HAIs is one of the prominent factors driving the demand for ATP swab tests.

The implementation of safety measures to prevent the spread of COVID-19 is driving the adoption of adenosine triphosphate (ATP) swabs. Moreover, the major shift in focus toward microbial safety amid the pandemic is offering lucrative opportunities for the growth of the market players.

Market Dynamics

Drivers

  • Rising Prevalence of Healthcare-Associated Infections (HAI)
  • Increasing Emphasis on Food Safety

Restraint

  • Limitations of ATP Swab Tests

Opportunity

  • Growing Spending on Patient Safety and Care

Future Trend

  • Development of Adenylate (A3) Concentration Based Modern Sterility Monitoring System

Companies Mentioned

  • Hygiena, LLC
  • 3M
  • Charm Sciences, Inc.
  • Kikkoman Biochemifa
  • Neogen
  • Ecolab
  • Ruhof Healthcare Corporation
  • Luminultra Technologies Ltd.
  • Charles River Laboratories, Inc
  • Promicol
  • PCE Instruments
  • Promega Corporation
  • Merck KGaA

For more information about this report visit https://www.researchandmarkets.com/r/tk0ylc

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900